MindScape Retreat Releases Landmark Case Study Showing 70% Average Symptom Improvement in Parkinson's Patients Following Ibogaine Treatment in Mexico
Miami, FL May 02, 2025 --( PR.com )-- MindScape Retreat, a pioneer in clinical psychedelic therapy programs, has released the results of a transformative case series evaluating the safety and efficacy of a 14-day ibogaine treatment program for Parkinson's disease. The findings suggest that ibogaine, a naturally occurring psychoactive alkaloid, may offer disease-modifying benefits in PD through its unique neuroregenerative properties.
The study tracked 30 patients with idiopathic Parkinson's disease (PD), ranging in age from 45 to 72, who attended the retreat's specialized ibogaine protocol between January and April 2025. Most were at Hoehn & Yahr stage 2–3, with moderate motor symptoms despite optimized conventional therapy.
Key Findings from the Case Study
- 52% average symptom relief was recorded within the first 3–4 days, following several days of titrated ibogaine therapy.
- By Day 14, the average symptom reduction had reached 70%, with improvements observed in gait, bradykinesia, tremor, and muscle rigidity.
- 25% of participants who continued low-dose microdosing (5–10 mg Ibogaine TA, 2–3 times per week) post-retreat experienced further improvement or maintained peak function at the 2-month follow-up.
- No serious adverse events occurred. Side effects were mild and included nausea (40%), temporary dizziness (20%), and transient insomnia (15%).
Program Design and Protocol
The 14-day program utilized Ibogaine HCl and Ibogaine TA, administered in twice-daily doses (75–150 mg in the morning; 50–75 mg in the afternoon), adjusted based on each patient's response. Patients received:
- Personalized ibogaine dosing under 24/7 medical monitoring
- Daily UPDRS assessments (Unified Parkinson's Disease Rating Scale)
- Electrocardiogram (EKG) and vital sign monitoring
- Supplementary therapies including guided physical therapy, meditation, nutritional support, and optional 5-MeO-DMT integration sessions
Treatment emphasized neuroplastic repair over mere symptom masking. Ibogaine and its active metabolite noribogaine are believed to upregulate Glial Cell Line-Derived Neurotrophic Factor (GDNF) – a protein shown in research to promote dopaminergic neuron survival and regrowth, potentially reversing PD pathology.
Patient Outcomes: Restored Function and Mobility
One standout case involved a 62-year-old male who arrived wheelchair-bound with severe bradykinesia and freezing of gait. By Day 4, he was walking with a cane. By Day 13, he was independently mobile for over 30 meters and able to board a plane home using only minor assistance. His motor score improved by 61%, and his family described the transformation as 'nothing short of miraculous.'
Across the cohort:
Gait and balance scores improved by 85%
Bradykinesia improved by 70%
Rigidity reduced by 65%
Tremor severity dropped by 60%
Most patients also reported enhanced mood, sleep quality, and cognitive clarity, reflecting the broad neurochemical modulation provided by noribogaine.
Implications and Future Directions
According to MindScape's medical team, these results suggest ibogaine may represent a new frontier in neurorestorative therapies for Parkinson's disease. Unlike standard dopamine-replacement drugs, ibogaine targets upstream mechanisms of disease progression, potentially slowing neurodegeneration.
'This is more than symptom control it's about restoring function. The evidence of sustained improvement and the role of neurotrophic support from ibogaine is compelling,' said Dr. Calderon, Medical Director at MindScape Retreat.
MindScape plans to submit this case study for peer-reviewed publication and is currently coordinating a prospective observational follow-up study with academic partners to monitor long-term outcomes, including dopamine function and disease progression rates over 12+ months.
About MindScape Retreat
MindScape Retreat is a medically licensed psychedelic wellness center in Cozumel, Mexico, specializing in integrative ibogaine therapy for addiction, depression, trauma, and neurodegenerative conditions. The center offers evidence-based, physician-supervised programs combining plant medicine with clinical diagnostics, therapeutic integration, and long-term aftercare.
MindScape Retreat
Email: [email protected]
Ibogaine Treatment for Parkinsons
Case Study: https://www.mindscaperetreat.com/ibogaine-for-parkinsons-case-study
Contact Information:
MindScape Retreat
Dr. Omar Calderon
786-761-7729
Contact via Email
mindscaperetreat.com/ibogaine-treatment-clinic
Read the full story here: MindScape Retreat Releases Landmark Case Study Showing 70% Average Symptom Improvement in Parkinson's Patients Following Ibogaine Treatment in Mexico
Press Release Distributed by PR.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer
CHENGDU, China, June 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱®) in combination with the PD-L1 monoclonal antibody tagitanlimab (科泰莱®) was granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations. Breakthrough Therapy Designation is granted for treatment options that demonstrate significant clinical advantages over currently available treatments and is aimed at expediting the research, development and marketing of innovative treatment options that address clinically urgent medical needs. This designation is based on the efficacy and safety data from the non-squamous cohort of the Phase II OptiTROP-Lung01 study. This marks the fifth Breakthrough Therapy Designation granted to sac-TMT by the NMPA. Sac-TMT has previously received this designation for: Locally advanced or metastatic triple-negative breast cancer (TNBC) in July 2022; EGFR-mutant, locally advanced or metastatic NSCLC after progression on EGFR-TKI therapy in January 2023; Locally advanced or metastatic hormone-receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) in patients who have previously received at least two lines of systemic chemotherapy in June 2023； First-line treatment of unresectable locally advanced, recurrent or metastatic PD-L1 negative TNBC in March 2024. Results from a Phase 2 OptiTROP-Lung01 study of sac-TMT in combination with tagitanlimab in first-line advanced or metastatic non-squamous NSCLC patients were presented in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting[1]. Dr. Michael Ge, CEO of Kelun-Biotech said, "This designation by the NMPA highlights the importance of developing novel therapeutic options for diverse NSCLC subtypes. Sac-TMT in combination with tagitanlimab demonstrated clinically meaningful outcomes in key endpoints for patients with non-squamous NSCLC without actionable genomic alterations as a first-line treatment. We are excited about the therapeutic potential of TROP2 ADC- immunotherapy combinations, and we look forward to working with regulatory authorities in China to bring this combination therapy to patients in need as soon as possible." [1] Abstract #8529: Lung Cancer – Non-Small Cell Metastatic, ASCO Annual Meeting, 2025 About sac-TMT (佳泰莱®)Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic HR+/HER2- BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the CDE, and were included in the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab2 or other agents for several types of cancer. These studies are sponsored and led by MSD. About Tagitanlimab (科泰莱®)Tagitanlimab is the first PD-L1 mAb globally to receive authorization for the first-line treatment of NPC. Previously, the NMPA has approved the marketing in China of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of patients with R/M NPC and monotherapy for the treatment of patients with recurrent or metastatic NPC who have failed after prior 2L+ chemotherapy, respectively. About Kelun-BiotechKelun-Biotech ( is a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
USA Today
15 hours ago
- USA Today
Bill Plaschke reveals Parkinson's disease diagnosis: 'It hurts to even say it.'
Bill Plaschke reveals Parkinson's disease diagnosis: 'It hurts to even say it.' Show Caption Hide Caption Kon Knueppel on the drive of former Duke teammate Cooper Flagg Kon Knueppel chats with Bryan Kalbrosky ahead of the NBA Draft about his former teammate Cooper Flagg and what makes him special Sports Seriously Bill Plaschke, the award-winning Los Angeles Times columnist and longtime "Around the Horn" panelist on ESPN, revealed this week that he has Parkinson's disease. He made the announcement as part of an LA Times column about a boxing program he attends for those trying to slow the effects of the condition. "I've got Parkinson's, and it hurts to even say it," Plaschke wrote. "I'm still mobile, still active, I don't have the trademark tremors that distinguish the famously afflicted Michael J. Fox or the late Muhammed Ali but, damn it, I've got it." Plaschke, 66, noted that he was diagnosed with Parkinson's four years ago after feeling weakness in his right arm, but had only told his family until now. The neurodegenerative disease has no cure and progressively impacts how a person moves and speaks. OPINION: Don't forget harsh price NFL players pay Plaschke wrote that it's a struggle for him to get dressed and "my pills come in gallon jugs and I spend entire Dodger games trying to discreetly swallow them in the press box." "I don't smile as much now," he added. "It's harder to smile when afflicted with the trademark Parkinson's masked face. When I FaceTime with my darlin Daisy, I worry she won't see past my dour expression and never know how much her granddaddy loves her." Plaschke has written for the Los Angeles Times since 1988 and became a sports columnist there in 1996. He has been named the national sports columnist of the year by the Associated Press Sports Editors nine times and is a member of the National Sports Media Hall of Fame and California Sports Hall of Fame. He was also one of the original panelists on "Around the Horn," beginning in 2002, and remained a regular contributor to the show until its 23-year run ended last month. Plaschke sounded a hopeful note at the end of his column, citing the inspiration provided by Kaizen Kinetics and everyone else dealing with Parkinson's disease through its boxing program. "I have Parkinson's," Plaschke wrote, "But, by God, it doesn't have me."
Yahoo
18 hours ago
- Yahoo
MAIA Biotechnology to Present at BIO International Convention 2025
CHICAGO, June 10, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its participation in the upcoming BIO (Biotechnology Innovation Organization) International Convention 2025 taking place June 16-19, 2025, in Boston, Massachusetts. MAIA Chairman and CEO Vlad Vitoc, MD, MBA will deliver a presentation featuring the latest findings from the Company's THIO-101 Phase 2 clinical trial evaluating ateganosine (THIO) sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC). Ateganosine is a small molecule telomere-targeting anticancer agent that acts by producing direct telomeric DNA damage and inducing cancer-specific immune responses. THIO-101 is expected to be the first completed clinical study of a telomere-targeting agent in the field of cancer drug discovery and treatment. MAIA recently announced the design for the expansion of the THIO-101 trial, which will further assess the efficacy of treatment in third-line NSCLC patients. Presentation DetailsSession date and time: June 18 at 11:30 AM EDTPresenter: Vlad Vitoc, MD, MBA Registered participants may request a meeting with MAIA management via the BIO Partnering™ platform on the BIO 2025 website. About BIO BIO (Biotechnology Innovation Organization) is the world's largest advocacy association representing biotechnology companies, academic and research institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. About Ateganosine Ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2'-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. About THIO-101, a Phase 2 Clinical Trial THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine's anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using overall response rate (ORR) as the primary clinical endpoint. The expansion of the study will assess ORR in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has been generally well-tolerated to date in a heavily pre-treated population. For more information on this Phase 2 trial, please visit using the identifier NCT05208944. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit Forward Looking Statements MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as "may," "might," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, "MAIA," "Company," "we," "our," and "us" refers to MAIA Biotechnology, Inc. and its subsidiaries. View source version on Contacts Investor Relations Contact +1 (872) 270-3518ir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
